The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project: a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification

<p>Abstract</p> <p>Background</p> <p>Many opiate users entering British prisons require prescribed medication to help them achieve abstinence. This commonly takes the form of a detoxification regime. Previously, a range of detoxification agents have been prescribed with...

Full description

Bibliographic Details
Main Authors: Li Ryan, Adams Clive E, El-Sayeh Hany G, Wright Nat MJ, Sheard Laura, Tompkins Charlotte NE
Format: Article
Language:English
Published: BMC 2009-02-01
Series:Substance Abuse Treatment, Prevention, and Policy
Online Access:http://www.substanceabusepolicy.com/content/4/1/1
id doaj-d574e68752544d2790261a8d12450f9c
record_format Article
spelling doaj-d574e68752544d2790261a8d12450f9c2020-11-24T21:58:28ZengBMCSubstance Abuse Treatment, Prevention, and Policy1747-597X2009-02-0141110.1186/1747-597X-4-1The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project: a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxificationLi RyanAdams Clive EEl-Sayeh Hany GWright Nat MJSheard LauraTompkins Charlotte NE<p>Abstract</p> <p>Background</p> <p>Many opiate users entering British prisons require prescribed medication to help them achieve abstinence. This commonly takes the form of a detoxification regime. Previously, a range of detoxification agents have been prescribed without a clear evidence base to recommend a drug of choice. There are few trials and very few in the prison setting. This study compares dihydrocodeine with buprenorphine.</p> <p>Methods</p> <p>Open label, pragmatic, randomised controlled trial in a large remand prison in the North of England. Ninety adult male prisoners requesting an opiate detoxification were randomised to receive either daily sublingual buprenorphine or daily oral dihydrocodeine, given in the context of routine care. All participants gave written, informed consent. Reducing regimens were within a standard regimen of not more than 20 days and were at the discretion of the prescribing doctor. Primary outcome was abstinence from illicit opiates as indicated by a urine test at five days post detoxification. Secondary outcomes were collected during the detoxification period and then at one, three and six months post detoxification. Analysis was undertaken using relative risk tests for categorical data and unpaired t-tests for continuous data.</p> <p>Results</p> <p>64% of those approached took part in the study. 63 men (70%) gave a urine sample at five days post detoxification. At the completion of detoxification, by intention to treat analysis, a higher proportion of people allocated to buprenorphine provided a urine sample negative for opiates (abstinent) compared with those who received dihydrocodeine (57% vs 35%, RR 1.61 CI 1.02–2.56). At the 1, 3 and 6 month follow-up points, there were no significant differences for urine samples negative for opiates between the two groups. Follow up rates were low for those participants who had subsequently been released into the community.</p> <p>Conclusion</p> <p>These findings would suggest that dihydrocodeine should not be routinely used for detoxification from opiates in the prison setting. The high relapse rate amongst those achieving abstinence would suggest the need for an increased emphasis upon opiate maintenance programmes in the prison setting.</p> <p>Trial registration</p> <p>Current Controlled Trials ISRCTN07752728</p> http://www.substanceabusepolicy.com/content/4/1/1
collection DOAJ
language English
format Article
sources DOAJ
author Li Ryan
Adams Clive E
El-Sayeh Hany G
Wright Nat MJ
Sheard Laura
Tompkins Charlotte NE
spellingShingle Li Ryan
Adams Clive E
El-Sayeh Hany G
Wright Nat MJ
Sheard Laura
Tompkins Charlotte NE
The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project: a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification
Substance Abuse Treatment, Prevention, and Policy
author_facet Li Ryan
Adams Clive E
El-Sayeh Hany G
Wright Nat MJ
Sheard Laura
Tompkins Charlotte NE
author_sort Li Ryan
title The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project: a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification
title_short The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project: a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification
title_full The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project: a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification
title_fullStr The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project: a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification
title_full_unstemmed The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project: a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification
title_sort leeds evaluation of efficacy of detoxification study (leeds) prisons project: a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification
publisher BMC
series Substance Abuse Treatment, Prevention, and Policy
issn 1747-597X
publishDate 2009-02-01
description <p>Abstract</p> <p>Background</p> <p>Many opiate users entering British prisons require prescribed medication to help them achieve abstinence. This commonly takes the form of a detoxification regime. Previously, a range of detoxification agents have been prescribed without a clear evidence base to recommend a drug of choice. There are few trials and very few in the prison setting. This study compares dihydrocodeine with buprenorphine.</p> <p>Methods</p> <p>Open label, pragmatic, randomised controlled trial in a large remand prison in the North of England. Ninety adult male prisoners requesting an opiate detoxification were randomised to receive either daily sublingual buprenorphine or daily oral dihydrocodeine, given in the context of routine care. All participants gave written, informed consent. Reducing regimens were within a standard regimen of not more than 20 days and were at the discretion of the prescribing doctor. Primary outcome was abstinence from illicit opiates as indicated by a urine test at five days post detoxification. Secondary outcomes were collected during the detoxification period and then at one, three and six months post detoxification. Analysis was undertaken using relative risk tests for categorical data and unpaired t-tests for continuous data.</p> <p>Results</p> <p>64% of those approached took part in the study. 63 men (70%) gave a urine sample at five days post detoxification. At the completion of detoxification, by intention to treat analysis, a higher proportion of people allocated to buprenorphine provided a urine sample negative for opiates (abstinent) compared with those who received dihydrocodeine (57% vs 35%, RR 1.61 CI 1.02–2.56). At the 1, 3 and 6 month follow-up points, there were no significant differences for urine samples negative for opiates between the two groups. Follow up rates were low for those participants who had subsequently been released into the community.</p> <p>Conclusion</p> <p>These findings would suggest that dihydrocodeine should not be routinely used for detoxification from opiates in the prison setting. The high relapse rate amongst those achieving abstinence would suggest the need for an increased emphasis upon opiate maintenance programmes in the prison setting.</p> <p>Trial registration</p> <p>Current Controlled Trials ISRCTN07752728</p>
url http://www.substanceabusepolicy.com/content/4/1/1
work_keys_str_mv AT liryan theleedsevaluationofefficacyofdetoxificationstudyleedsprisonsprojectarandomisedcontrolledtrialcomparingdihydrocodeineandbuprenorphineforopiatedetoxification
AT adamsclivee theleedsevaluationofefficacyofdetoxificationstudyleedsprisonsprojectarandomisedcontrolledtrialcomparingdihydrocodeineandbuprenorphineforopiatedetoxification
AT elsayehhanyg theleedsevaluationofefficacyofdetoxificationstudyleedsprisonsprojectarandomisedcontrolledtrialcomparingdihydrocodeineandbuprenorphineforopiatedetoxification
AT wrightnatmj theleedsevaluationofefficacyofdetoxificationstudyleedsprisonsprojectarandomisedcontrolledtrialcomparingdihydrocodeineandbuprenorphineforopiatedetoxification
AT sheardlaura theleedsevaluationofefficacyofdetoxificationstudyleedsprisonsprojectarandomisedcontrolledtrialcomparingdihydrocodeineandbuprenorphineforopiatedetoxification
AT tompkinscharlottene theleedsevaluationofefficacyofdetoxificationstudyleedsprisonsprojectarandomisedcontrolledtrialcomparingdihydrocodeineandbuprenorphineforopiatedetoxification
AT liryan leedsevaluationofefficacyofdetoxificationstudyleedsprisonsprojectarandomisedcontrolledtrialcomparingdihydrocodeineandbuprenorphineforopiatedetoxification
AT adamsclivee leedsevaluationofefficacyofdetoxificationstudyleedsprisonsprojectarandomisedcontrolledtrialcomparingdihydrocodeineandbuprenorphineforopiatedetoxification
AT elsayehhanyg leedsevaluationofefficacyofdetoxificationstudyleedsprisonsprojectarandomisedcontrolledtrialcomparingdihydrocodeineandbuprenorphineforopiatedetoxification
AT wrightnatmj leedsevaluationofefficacyofdetoxificationstudyleedsprisonsprojectarandomisedcontrolledtrialcomparingdihydrocodeineandbuprenorphineforopiatedetoxification
AT sheardlaura leedsevaluationofefficacyofdetoxificationstudyleedsprisonsprojectarandomisedcontrolledtrialcomparingdihydrocodeineandbuprenorphineforopiatedetoxification
AT tompkinscharlottene leedsevaluationofefficacyofdetoxificationstudyleedsprisonsprojectarandomisedcontrolledtrialcomparingdihydrocodeineandbuprenorphineforopiatedetoxification
_version_ 1725851818601218048